EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Exploring the impact of patient‐specific clinical features on osimertinib effectiveness in a real‐world cohort of patients with EGFR mutated non‐small cell lung cancer

Ard van Veelen iD, G D Marijn Veerman, Marjon V Verschueren, Judith L Gulikers, Christi M J Steendam, Anita J W M Brouns, Safiye Dursun, Marthe S Paats, Vivianne C G Tjan-Heijnen, Cor van der Leest, Anne-Marie C Dingemans, Ron H J Mathijssen und 6 weitere

International Journal of Cancer · 15.01.2024 · 154 (2) · 332-342

DOI: 10.1002/ijc.34742 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Cancer, online erschienen am 15.10.2023. Verfasst von Ard van Veelen und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy & Toxicology, Maastricht University Medical Center+, Maastricht, The Netherlands. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osimertinib is prescribed to patients with metastatic non‐small cell lung cancer (NSCLC) and a sensitizing EGFR mutation. Limited data exists on the impact of patient characteristics or osimertinib exposure on effectiveness outcomes. This was a Dutch, multicenter cohort study. Eligible patients were ≥18 years, with metastatic EGFR m + NSCLC, receiving osimertinib. Primary endpoint was progression‐free survival (PFS). Secondary endpoints included overall survival (OS) and safety. Kaplan‐Meier analyses and multivariate Cox proportional hazard models were performed. In total, 294 patients were included. Primary EGFR ‐mutations were mainly exon 19 deletions (54%) and p.L858R point mutations (30%). Osimertinib was given in first‐line (40%), second‐line (46%) or beyond (14%), with median PFS 14.4 (95% CI: 9.4‐19.3), 13.9 (95% CI: 11.3‐16.1) and 8.7 months (95% CI: 4.6‐12.7), respectively. Patients with low BMI (271 ng/mL) had shorter PFS compared to a low C min,SS (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsFemaleHumansMaleCohort StudiesProtein Kinase InhibitorsErbB ReceptorsAniline CompoundsMutationAcrylamidesIndolesPyrimidines

Stichwörter der Autor:innen

BMIagefirst-line treatmentlung cancerobservational studyosimertinibplasma trough concentrationreal-world treatment

Substanzen

Protein Kinase InhibitorsErbB ReceptorsAniline CompoundsosimertinibAcrylamidesIndolesPyrimidinesEGFR protein, human

Autor:innen und Institutionen

  • Department of Clinical Pharmacy & Toxicology, Maastricht University Medical Center+, Maastricht, The Netherlands.
  • CARIM School for Cardiovascular Disease, Maastricht University Medical Center+, Maastricht, The Netherlands.
  • Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands.
  • Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Department of Clinical Pharmacy, St. Antonius Hospital, Utrecht/Nieuwegein, The Netherlands.
  • Department of Respiratory Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.

ORCID-Profile: Ard van Veelen

Zitieren

APA

van Veelen, A., Veerman, G. D. M., Verschueren, M. V., Gulikers, J. L., Steendam, C. M. J., Brouns, A. J. W. M., Dursun, S., Paats, M. S., Tjan-Heijnen, V. C. G., van der Leest, C., Dingemans, A. C., Mathijssen, R. H. J., van de Garde, E. M. W., Souverein, P., Driessen, J. H. M., Hendriks, L. E. L., van Geel, R. M. J. M., & Croes, S. (2024). Exploring the impact of patient‐specific clinical features on osimertinib effectiveness in a real‐world cohort of patients with EGFR mutated non‐small cell lung cancer. International Journal of Cancer, 154(2), 332-342. https://doi.org/10.1002/ijc.34742

Vancouver

van Veelen A, Veerman GDM, Verschueren MV, Gulikers JL, Steendam CMJ, Brouns AJWM, et al. Exploring the impact of patient‐specific clinical features on osimertinib effectiveness in a real‐world cohort of patients with EGFR mutated non‐small cell lung cancer. International Journal of Cancer. 2024;154(2):332-342. doi:10.1002/ijc.34742

BibTeX
@article{vanVeelen2024,
  author = {van Veelen, Ard and Veerman, G D Marijn and Verschueren, Marjon V and Gulikers, Judith L and Steendam, Christi M J and Brouns, Anita J W M and Dursun, Safiye and Paats, Marthe S and Tjan-Heijnen, Vivianne C G and van der Leest, Cor and Dingemans, Anne-Marie C and Mathijssen, Ron H J and van de Garde, Ewoudt M W and Souverein, Patrick and Driessen, Johanna H M and Hendriks, Lizza E L and van Geel, Robin M J M and Croes, Sander},
  title = {Exploring the impact of patient‐specific clinical features on osimertinib effectiveness in a real‐world cohort of patients with EGFR mutated non‐small cell lung cancer},
  journal = {International Journal of Cancer},
  year = {2024},
  volume = {154},
  number = {2},
  pages = {332--342},
  doi = {10.1002/ijc.34742}
}
Kostenlos starten →